CIK 0001824893
- Non-accelerated filer
- Smaller reporting company
Surrozen, Inc./DE
Sign in to watch- Ticker
- SRZN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 301374889
- Phone
- +1 650-475-2820
- Business address
- 171 OYSTER POINT BLVD, SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- Consonance-HFW Acquisition Corp.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-10-10 | Vanhove Geertrui Chief Medical Officer | Grant or award · Option (right to buy) | +24,587 | 24,587 | ||
| 2022-10-10 | Vanhove Geertrui Chief Medical Officer | Grant or award · Option (right to buy) | +1,760 | 1,760 | ||
| 2022-10-10 | Williams Charles O Chief Financial Officer | Returned to the company · Option (right to buy) | −77,972 | 0 | ||
| 2022-10-10 | Williams Charles O Chief Financial Officer | Returned to the company · Option (right to buy) | −2,433 | 0 | ||
| 2022-10-10 | Williams Charles O Chief Financial Officer | Returned to the company · Option (right to buy) | −12,164 | 0 | ||
| 2022-10-10 | Williams Charles O Chief Financial Officer | Returned to the company · Option (right to buy) | −97,676 | 0 | ||
| 2022-10-10 | Williams Charles O Chief Financial Officer | Grant or award · Option (right to buy) | +12,164 | 12,164 | ||
| 2022-10-10 | Williams Charles O Chief Financial Officer | Grant or award · Option (right to buy) | +97,676 | 97,676 | ||
| 2022-10-10 | Williams Charles O Chief Financial Officer | Grant or award · Option (right to buy) | +2,433 | 2,433 | ||
| 2022-10-10 | Williams Charles O Chief Financial Officer | Grant or award · Option (right to buy) | +77,972 | 77,972 | ||
| 2022-10-10 | Yeh Wen-Chen Chief Scientific Officer | Returned to the company · Option (right to buy) | −29,567 | 0 | ||
| 2022-10-10 | Yeh Wen-Chen Chief Scientific Officer | Returned to the company · Option (right to buy) | −5,562 | 0 | ||
| 2022-10-10 | Yeh Wen-Chen Chief Scientific Officer | Grant or award · Option (right to buy) | +5,562 | 5,562 | ||
| 2022-10-10 | Yeh Wen-Chen Chief Scientific Officer | Grant or award · Option (right to buy) | +29,567 | 29,567 | ||
| 2022-10-10 | Parker Craig C Chief Executive Officer | Returned to the company · Option (right to buy) | −35,987 | 0 | ||
| 2022-10-10 | Parker Craig C Chief Executive Officer | Returned to the company · Option (right to buy) | −2,065 | 0 | ||
| 2022-10-10 | Parker Craig C Chief Executive Officer | Returned to the company · Option (right to buy) | −181,270 | 0 | ||
| 2022-10-10 | Parker Craig C Chief Executive Officer | Returned to the company · Option (right to buy) | −315,310 | 0 | ||
| 2022-10-10 | Parker Craig C Chief Executive Officer | Grant or award · Option (right to buy) | +35,987 | 35,987 | ||
| 2022-10-10 | Parker Craig C Chief Executive Officer | Grant or award · Option (right to buy) | +315,310 | 315,310 |
Page 14 of 20 · 398 trades